From June 5-8, 2023, the 2023 Biotechnology Innovation Organization International Convention (“BIO 2023”) will be held in Boston, Massachusetts, USA and Henlius will showcase a wide range of innovative research and development accomplishments for conference attendees.

BIO International Convention is the world’s largest gathering of the biotechnology industry along with industry-leading investor and partnering meetings held around the world. It is produced by BIO (Biotechnology Innovation Organization), which is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.

Henlius is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Up to date, 5 products have been launched in China, 1 has been approved for marketing in overseas markets, 18 indications are approved worldwide, and 3 marketing applications have been accepted for review in China, the U.S., and the EU, respectively.

During BIO 2023, the company will be at Booth #1635 with 5 launched products, including HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab for injection, trade name in Europe: Zercepac^®; trade names in Australia: Tuzucip^® and Trastucip^®, the first China-developed mAb biosimilar approved both in China and Europe, HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), and its innovative product HANSIZHUANG, the world’s first anti-PD-1 mAb for the first-line treatment of SCLC. Apart from the launched products, Henlius has pro-actively built a diversified and high-quality product pipeline with a focus on oncology, autoimmune diseases, and ophthalmic diseases, covering over 20 innovative monoclonal antibodies (mAbs) and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone.

Henlius is determined to offer high-quality, affordable, and innovative biologic medicines for patients worldwide, focuses on game-changing innovations, and aggressively pursues anti-tumour research and international collaboration. We warmly invite you to visit and connect with us at booth #1635 at the Boston Convention & Exhibition Center.